Sorafenib treatment following hematopoietic stem cell transplant in pediatric <i>FLT3</i>/ITD acute myeloid leukemia

Abstract

Our case series suggests that sorafenib administration is feasible and tolerable in pediatric FLT3/ITD+ AML patients early post HSCT. Ongoing prospective controlled studies are needed to further define the dosing of sorafenib in the post-HSCT period and to determine the optimal context for this treatment approach.